[144] PRECIGEN, INC. SEC Filing

Rhea-AI Filing Summary

PRECIGEN, Inc. (PGEN) Form 144 notice shows a proposed sale of 67,523 shares of Common Stock through Goldman Sachs & Co. LLC on 09/29/2025 for an aggregate market value of $245,108.49. The filing states there are 352,910,331 shares outstanding, so the proposed sale represents approximately 0.019% of outstanding shares.

The shares were acquired as restricted stock awards or restricted stock units from the issuer between 03/23/2019 and 03/25/2021, in tranches of 7,911; 24,703; 34,328; and 581 shares. The filer reports nothing to report for securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Insights

Financial Analyst

TL;DR: A small, routine insider sale notice; proceeds (~$245k) are immaterial to market capitalization.

The Form 144 discloses an insider plan to sell 67,523 shares valued at $245,108.49, representing roughly 0.019% of total shares outstanding. The shares were received as compensation (RSAs/RSUs) between 2019 and 2021 and no shares were reported sold in the prior three months. From a financial-materiality standpoint, the size and value are negligible relative to the issuer's outstanding equity, indicating limited market impact. The filing meets Rule 144 disclosure requirements and contains the standard attestation regarding undisclosed material information.

Corporate Governance Expert

TL;DR: Routine compliance disclosure of an insider sale; no governance red flags evident from the notice alone.

The notice documents a proposed sale executed through Goldman Sachs and provides acquisition dates and amounts for the underlying restricted awards, demonstrating transparency and adherence to Rule 144 procedures. There is no reportable activity in the prior three months and the filer affirms no undisclosed material adverse information. Absent additional context (e.g., officer identity, timing relative to company events), this filing does not, by itself, indicate governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	67523	245108.49	352910331	09/29/2025	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/25/2021	Acquired as compensation -- Restricted Stock Awards	The Issuer			581	03/25/2021	Compensation
Common Stock	03/23/2019	Acquired as compensation -- Restricted Stock Units	The Issuer			7911	03/23/2019	Compensation
Common Stock	03/08/2020	Acquired as compensation -- Restricted Stock Units	The Issuer			24703	03/08/2020	Compensation
Common Stock	03/22/2020	Acquired as compensation -- Restricted Stock Units	The Issuer			34328	03/22/2020	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Precigen's (PGEN) Form 144 disclose?

The filing discloses a proposed sale of 67,523 common shares via Goldman Sachs on 09/29/2025 with an aggregate market value of $245,108.49.

How large is the proposed sale relative to PGEN's outstanding shares?

The sale is about 0.019% of the reported 352,910,331 shares outstanding.

When were the shares being sold originally acquired?

The shares were granted as compensation (RSAs/RSUs) on 03/23/2019, 03/08/2020, 03/22/2020, and 03/25/2021.

Were any securities of the issuer sold by the filer in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.

Through which broker will the shares be sold?

The proposed sale is to be conducted through Goldman Sachs & Co. LLC, address listed in the filing.